A pharmacokinetic interaction and safety and efficacy phase II, open label study with a safety lead-in evaluating docetaxel plus tesmilifene (YMB1002) in patients with metastatic breast cancer suitable for treatment with docetaxel

Trial Profile

A pharmacokinetic interaction and safety and efficacy phase II, open label study with a safety lead-in evaluating docetaxel plus tesmilifene (YMB1002) in patients with metastatic breast cancer suitable for treatment with docetaxel

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2009

At a glance

  • Drugs Tesmilifene (Primary) ; Docetaxel
  • Indications Advanced breast cancer
  • Focus Pharmacokinetics
  • Sponsors YM BioSciences
  • Most Recent Events

    • 08 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top